Living with metastatic breast cancer: A global patient survey

Community Oncology

Volumn 7, Issue 9, 2010, Pages 406-412

  Mayer, Musa ^a   Huñis, Adrián ^b   Oratz, Ruth ^c   Glennon, Cathy ^d   Spicer, Pat ^e   Caplan, Elyse ^f   Fallowfield, Lesley ^g  

^a AdvancedBCorg   (United States)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF KANSAS HOSPITAL   (United States)

^e CancerCare of Long Island   (United States)

^f Living Beyond Breast Cancer   (United States)

^g BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; ATTITUDE TO ILLNESS; BREAST CANCER; CONTROLLED STUDY; DISEASE SEVERITY; EARLY CANCER; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE NEED; HEALTH SURVEY; HUMAN; LIFE EVENT; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PATIENT ATTITUDE; PSYCHOSOCIAL CARE; QUESTIONNAIRE; WOMEN'S HEALTH;

EID: 78549279127     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70415-6     Document Type: Article

References (16)

1. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005;10:20-29.
2. Anyanwu SN. Temporal trends in breast cancer presentation in the third world. J Exp Clin Cancer Res 2008;27:17.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. World Health Organization. Stewart BW, Kleihues P, eds. World Cancer Report. Lyon, France: IARC Press; 2003.
5. Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007;110:973-979.
6. Surveillance Epidemiology and End Results (SEER) Stat Database, NCI. http://www. seer.cancer.gov. Accessed January 15, 2010.
7. Ernst MF, van de Poll-Franse LV, Roukema JA, et al. Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast 2007;16:344-351.
8. Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005;104:1742-1750.
9. Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer 2004;100:44-52.
10. The BRIDGE (Bridging Gaps, Expanding Outreach) Survey Web site. http:// www.bridgembc.com. Accessed January 15, 2010.
11. Mayer M, Hunis A, Oratz R, et al. Evaluating the needs of women living with metastatic breast cancer: a global survey. Paper presented at: 11th Bi-Annual Conference on Primary Therapy of Early Breast Cancer; March 11-14, 2009; St Gallen, Switzerland. Abstract 235.
12. Fallowfield L, Hunis A, Oratz R, et al. Identifying barriers preventing clinical trial enrollment: results of a global survey of patients with metastatic breast cancer. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; April 18-22, 2009; Denver, CO. Abstract 4836.
13. Mayer M, Hunis A, Oratz R, et al. Importance of providing tailored resources to patients with metastatic breast cancer: results of the Global BRIDGE Survey. Presented at the 32nd San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Abstract 3085.
14. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009;27:4515-4521.
15. Simon M, Du W, Flaherty L, et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 2004;22:2046-2052.
16. Mayer M, Grober S. Silent voices: women with metastatic breast cancer share their needs and preferences for information, support and practical services. Living Beyond Breast Cancer, 2006. http://www.lbbc.org/data/news/ LBBCsilentvoices.pdf. Accessed January 15, 2010.